One-time infusion of anzu-cel (anzutresgene autoleucel, IMA203) PRAME cell therapy induced rapid, deep and durable systemic ...

Researchers evaluated the prognostic value of 1-year tumor volume regression in patients with uveal melanoma treated with plaque brachytherapy.

A new study identified the elements that could determine the overall survival of patients with the metastatic eye tumor, uveal melanoma. Patients with metastatic uveal melanoma (UM) experienced ...

New research from the University of Pittsburgh explains why metastatic uveal melanoma is resistant to conventional immunotherapies and how adoptive therapy, which involves growing a patient's T cells ...

Researchers at Queen Mary's Barts Cancer Institute have found a more active approach to monitoring and treating people with a rare eye cancer (known as uveal melanoma) that has spread to the liver ...

MADRID -- The significant survival benefit with the bispecific T-cell receptor therapy tebentafusp (Kimmtrak) held up at 3 years for selected patients with previously untreated metastatic uveal ...

MarketBeat Week in Review – 7/15 - 7/19 IDEAYA Biosciences (NASDAQ:IDYA) executives highlighted recent clinical progress ...